These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29632637)

  • 1. RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer.
    Fujimoto D; Goi T; Koneri K; Hirono Y
    Oncotarget; 2018 Mar; 9(20):15208-15218. PubMed ID: 29632637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.
    Kurashige J; Watanabe M; Iwatsuki M; Kinoshita K; Saito S; Nagai Y; Ishimoto T; Baba Y; Mimori K; Baba H
    Br J Cancer; 2012 Oct; 107(8):1233-8. PubMed ID: 22955852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribophorin II Overexpression Is Associated with Poor Response to Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in P16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Chen WS; Luo SD; Chiu TJ; Wang YM; Chen WC; Chien CY; Fang FM; Huang TL; Li SH
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.
    Kubo T; Kawano Y; Himuro N; Sugita S; Sato Y; Ishikawa K; Takada K; Murase K; Miyanishi K; Sato T; Takimoto R; Kobune M; Nobuoka T; Hirata K; Takayama T; Mori M; Hasegawa T; Kato J
    Gastric Cancer; 2016 Jul; 19(3):827-38. PubMed ID: 26486506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines.
    Yuan TM; Liang RY; Chueh PJ; Chuang SM
    Oncol Lett; 2015 Apr; 9(4):1861-1868. PubMed ID: 25789057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study.
    Saito H; Fushida S; Miyashita T; Oyama K; Yamaguchi T; Tsukada T; Kinoshita J; Tajima H; Ninomiya I; Ohta T
    BMC Cancer; 2017 Apr; 17(1):294. PubMed ID: 28449652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.
    Fujita Y; Yagishita S; Takeshita F; Yamamoto Y; Kuwano K; Ochiya T
    Oncotarget; 2015 Feb; 6(5):3335-45. PubMed ID: 25595901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
    Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
    Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RPN2 gene confers docetaxel resistance in breast cancer.
    Honma K; Iwao-Koizumi K; Takeshita F; Yamamoto Y; Yoshida T; Nishio K; Nagahara S; Kato K; Ochiya T
    Nat Med; 2008 Sep; 14(9):939-48. PubMed ID: 18724378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer.
    Quintero-Aldana G; Jorge M; Grande C; Salgado M; Gallardo E; Varela S; López C; Villanueva MJ; Fernández A; Alvarez E; González P; Castellanos J; Casal J; López R; Campos Balea B
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):731-7. PubMed ID: 26242221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression and clinical significance of ribophorin II (RPN2) in human breast cancer.
    Ono M; Tsuda H; Kobayashi T; Takeshita F; Takahashi RU; Tamura K; Akashi-Tanaka S; Moriya T; Yamasaki T; Kinoshita T; Yamamoto J; Fujiwara Y; Ochiya T
    Pathol Int; 2015 Jun; 65(6):301-8. PubMed ID: 25881688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ribophorine II is a promising prognostic factor in human gastric adenocarcinoma.
    Fujimoto D; Goi T; Hirono Y
    Int J Oncol; 2017 Feb; 50(2):448-456. PubMed ID: 28035352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer.
    Kim JY; Ryoo HM; Bae SH; Kang BW; Chae YS; Yoon S; Baek JH; Kim MK; Lee KH; Lee SA; Song HS; Kim JG
    Anticancer Res; 2015 Jun; 35(6):3531-6. PubMed ID: 26026121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
    Urano N; Fujiwara Y; Doki Y; Kim SJ; Miyoshi Y; Noguchi S; Miyata H; Takiguchi S; Yasuda T; Yano M; Monden M
    Int J Oncol; 2006 Feb; 28(2):375-81. PubMed ID: 16391792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.